CORT

Corcept TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$60.00

-15.7% vs current

Most likely

Base case

45%

Probability

Target price

$50.00

-29.8% vs current

B-

Bear case

25%

Probability

Target price

$34.00

-52.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-22

AI commentary

Sentiment is constructive but still monitoring-oriented. The evidence packet and primary sources support a positive thesis change versus a pre-approval setup because Corcept now has FDA-approved ovarian-cancer therapy, full ROSELLA survival data, and a real commercial catalyst path. However, conviction should stay moderate rather than aggressive: the stock still carries concentration risk, hypercortisolism suffered a CRL, and 2026 upside requires proof that Lifyorli launch demand and follow-on data can offset generic pressure in the legacy business. Overall, this looks like a favorable but not fully de-risked transition story.

RankAlpha Sentiment Codex - 2026-04-22

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystInitial Lifyorli launch and demand capture after FDA approvalHigh impact

The March 25, 2026 FDA approval of Lifyorli for platinum-resistant ovarian cancer created Corcept's first approved oncology launch, and management has framed 2026 as a commercialization year with $900-$1,000 million revenue guidance while also saying the specialty-pharmacy transition is complete and February was tracking toward a record month for new patient starts. Near-term upside depends on whether launch uptake and channel execution offset prior fulfillment friction and begin to broaden the revenue base beyond Korlym. Supported by [#8-K-2026-03-25] and [#IR-2026-02-24].

2026-12-31eventBELLA ovarian-cancer data expected by year-end 2026High impact

Corcept said results from BELLA in advanced ovarian cancer should be available by the end of 2026, giving investors a concrete next efficacy/expansion checkpoint beyond ROSELLA and the initial Lifyorli launch. Positive BELLA data would support the view that glucocorticoid receptor modulation can extend beyond the approved setting, while weak or inconclusive data would narrow the oncology platform story. Supported by [#IR-2026-02-24].

2026-12-31catalystROSELLA survival data and guideline positioning can support a broader oncology platformHigh impact

Corcept's April 10, 2026 ROSELLA update showed a 35% reduction in risk of death, 4.1 months of median overall-survival benefit, and NCCN preferred-regimen inclusion following March approval. If those outcomes translate into durable prescribing traction and support additional ovarian and solid-tumor studies, investors may increasingly value Corcept as more than a single-product endocrine company. This remains only partially proven because commercial uptake and follow-on trial execution still need to confirm the platform narrative. Supported by [#IR-2026-04-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-22 • Updated nightlySource: Internal modelMethodology